MS trading volume has added 6045374 shares compared to readings over the past three months as it recently exchanged 17535374 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 11490000 shares, and this is 1.53 times the normal volume. A look at its technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 40.2 point.
Morgan Stanley (NYSE:MS) dipped by -11.1% over the past three months which led to its overall six-month decrease to stand at -18.28%. The equity price sank -5.96% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a -7.01% fall over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -18.07% and is now down by -18.79% since start of this year.
The shares of Morgan Stanley dropped by -28.24% or -$16.77 from its last recorded high of $59.38 which it attained on March 12 to close at $42.61 per share. Over the past 52 weeks, the shares of Morgan Stanley has been trading as low as $42.32 before witnessing a massive surge by 0.69% or $0.29. This price movement has led to the MS stock receiving more attention and has become one to watch out for. It dipped by -1.18% on Thursday and this got the market worried. The stock’s beta now stands at 1.26 and when compared to its 200-day moving average and its 50-day moving average, MS price stands -14.81% below and -5.85% below respectively. Its average daily volatility for this week is 3.37% which is more than the 3.01% recorded over the past month.
Experts from research firms are bullish about the near-term performance of Morgan Stanley (MS) with most of them predicting a $58.54 price target on a short-term (12 months) basis. The average price target by the analysts will see a 37.39% rise in the stock and would lead to MS’s market cap to surge to $100.69B. The stock has been rated an average 2, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 28 analysts that track Morgan Stanley (NYSE:MS) and find out that 9 of them rated it as a Hold. 19 of the 19 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.
Analysts have predicted a price target for Sabra Health Care REIT, Inc. (SBRA) for 1 year and it stands at an average $21.38/share. This means that it would likely increase by 10.32% from its current position. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $18. On the other hand, one analyst is super bullish about the price, setting a target as high as $24.
The SBRA stock Stochastic Oscillator (%D) is at 46.16%, which means that it is currently neutral. The shares P/S ratio stands at 5.31 which compares to the 8.61 recorded by the industry or the 6.11 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 15.21, which is higher than the 8.88 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 21.8% over the past five years.
Analysts view Sabra Health Care REIT, Inc. (NASDAQ:SBRA) as a Hold, with 2.9 consensus rating. Reuters surveyed 12 analysts that follow SBRA and found that 9 of those analysts rated the stock as a Hold. The remaining 3 were divided, with 2 analyst rating it as a Buy or a Strong Buy while 1 analysts advised investors to desist from buying Sabra Health Care REIT, Inc. (SBRA) shares or sell it if they already own it.